贝瑞基因（000710）8月11日主力资金净流出2765.05万元

Group 1 - The core viewpoint of the news is that 贝瑞基因 (Berry Genomics) has experienced a decline in revenue and net profit in its latest quarterly report, indicating potential challenges for the company moving forward [1][3] - As of August 11, 2025, 贝瑞基因's stock closed at 14.97 yuan, with a 1.22% increase and a turnover rate of 8.0%, reflecting active trading [1] - The company's total revenue for Q1 2025 was 2.18 billion yuan, a year-on-year decrease of 22.08%, while the net profit attributable to shareholders was 646.22 million yuan, down 178.47% year-on-year [1] Group 2 - The company has a current liquidity ratio of 2.526 and a quick ratio of 2.180, indicating a strong short-term financial position [1] - The asset-liability ratio stands at 29.63%, suggesting a relatively low level of debt compared to its assets [1] - 贝瑞基因 has made investments in 12 companies and participated in 4 bidding projects, showcasing its engagement in business expansion and partnerships [2]